New data independently confirms safety profile of ATH434
Filed with ASX · · 3 pages · English
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Pause in Trading
- Meeting with US FDA provides development path for ATH434
- Presentation on ATH434 to American Academy of Neurology
- Appendix 4C and Quarterly Update
- NASDAQ Temporary Relief
Later from Alterity Therapeutics
- Preliminary Final Report
- Company update on Annual Report 2020
- Alterity raises $35M in placement to institutional investors
- Alterity completes Placement Tranche 1 raising $10M
- MSA patients enrolled in bioMUSE Study
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics